ERBB2 and colorectal carcinoma: The study data include two cohorts focusing on patients with colorectal cancer (CRC), one with ERBB2 amplifications and the other with either ERBB2 or ERBB3 (ERBB2/3) mutations, who received treatment with pertuzumab plus trastuzumab.